MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,592.00
+2.00 (0.13%)
At close: Aug 28, 2025
0.13%
Market Cap62.17B
Revenue (ttm)13.79B
Net Income (ttm)-4.93B
Shares Out39.05M
EPS (ttm)-131.38
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume130,598
Average Volume260,414
Open1,590.00
Previous Close1,590.00
Day's Range1,539.00 - 1,609.00
52-Week Range999.00 - 2,250.00
Beta1.37
RSI32.64
Earnings DateAug 14, 2025

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 41
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.